Various invasive and metastatic cancers have been associated with high level of E-cadherin expression, notably in patients with prostate cancer [36], ovarian cancer [37], and glioblastoma [38], thus suggesting that E-cadherin promotes metastasis in certain tumors instead of suppressing tumor progression. Here, CDH1 is linked to metastatic malignant neoplasm.